Vericel Corporation
VCEL
Rank in Stocks
#4674
Vericel Corporation operates as a biopharmaceutical firm that has reached the... Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Share Price
$58.39
Last synced: 2026-11-09
Market Cap
$2.99B
Change (1 day)
6.90%
Change (1 year)
42.24%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vericel Corporation (VCEL)
Category
Healthcare
EPS for Vericel Corporation (VCEL)
EPS as of September 2026 TTM: $0.66
According to Vericel Corporation's latest financial reports, its current EPS (TTM) is $0.66. At the end of 2025 the company had an EPS of $0.33, an increase over its 2024 EPS of $0.21.
EPS history for Vericel Corporation from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.66 | 100.00% |
| 2025 | $0.33 | 57.14% |
| 2024 | $0.21 | -413.90% |
| 2023 | $-0.07 | -80.89% |
| 2022 | $-0.35 | 118.75% |
| 2021 | $-0.16 | -352.76% |
| 2020 | $0.06 | -135.17% |
| 2019 | $-0.18 | -10.00% |
| 2018 | $-0.20 | -61.54% |
| 2017 | $-0.52 | -38.82% |
| 2016 | $-0.85 | 23.19% |
| 2015 | $-0.69 | -59.65% |
| 2014 | $-1.71 | -66.99% |
| 2013 | $-5.18 | -63.80% |
| 2012 | $-14.31 | 40.43% |
| 2011 | $-10.19 | -28.94% |
| 2010 | $-14.34 | -19.62% |
| 2009 | $-17.84 | -28.50% |
| 2008 | $-24.95 | 5.94% |
| 2007 | $-23.55 | -5.00% |
| 2006 | $-24.79 | 22.72% |
| 2005 | $-20.20 | -11.29% |
| 2004 | $-22.77 | -24.25% |
| 2003 | $-30.06 | -0.33% |
| 2002 | $-30.16 | 8.26% |
| 2001 | $-27.86 | -56.71% |
| 2000 | $-64.36 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 2,272.73% |
US
|
|
| $-7.07 | -1,171.21% |
US
|
|
| $-5.29 | -901.52% |
AU
|
|
| $12.88 | 1,851.53% |
BE
|
|
| $21.56 | 3,166.67% |
NL
|
Questions about Vericel Corporation's earnings per share (EPS)
What is Vericel Corporation's earnings per share (EPS)?
Vericel Corporation's earnings per share (EPS) over the last twelve months is $0.66, as of Sep 2026.
What was Vericel Corporation's earnings per share (EPS) in 2025?
In 2025, Vericel Corporation's earnings per share (EPS) was $0.33, 57.14% more than in 2024 ($0.21).
How has Vericel Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vericel Corporation's earnings per share (EPS) went from $0.06 to $0.33, an average growth of 40.63% a year.
How does Vericel Corporation's earnings per share (EPS) compare with similar companies?
Vericel Corporation's earnings per share (EPS) ($0.66) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.